Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: A propensity score-matched analysis

Kang Yin Chen, Seung Woon Rha, Lin Wang, Yong Jian Li, Guang Ping Li, Kanhaiya L. Poddar, Ji Young Park, Cheol Ung Choi, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Myung Ho Jeong, Young Keun Ahn, Taek Jong Hong, Young Jo Kim, Seung Ho Hur, In Whan Seong, Jei Keon Chae, Myeong Chan Cho, Jang Ho BaeDong Hoon Choi, Yang Soo Jang, In Ho Chae, Chong Jin Kim, Jung Han Yoon, Wook Sung Chung, Ki Bae Seung, Seung Jung Park

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: This study sought to compare everolimus-eluting stents (EES) with zotarolimus-eluting stents (ZES) in patients with acute myocardial infarction (AMI). Background: There is a paucity of data to exclusively evaluate the safety and efficacy of second-generation drug-eluting stents (DES) in the setting of AMI. Methods: The present study enrolled 3,309 AMI patients treated with ZES (n = 1,608) or EES (n = 1,701) in a large-scale, prospective, multicenter registry - KAMIR (Korea Acute Myocardial Infarction Registry). Propensity score matching was applied to adjust for differences in baseline clinical and angiographic characteristics, producing a total of 2,646 patients (1,343 receiving ZES, and 1,343 receiving EES). Target lesion failure (TLF) was defined as the composite of cardiac death, recurrent nonfatal myocardial infarction, or target lesion revascularization. Major clinical outcomes at 1 year were compared between the 2 propensity score-matched groups. Results: After propensity score matching, baseline clinical and angiographic characteristics were similar between the 2 groups. Clinical outcomes of the propensity score-matched patients showed that, despite similar incidences of recurrent nonfatal myocardial infarction and in-hospital and 1-year mortality, patients in the EES group had significantly lower rates of TLF (6.5% vs. 8.7%, p = 0.029) and probable or definite stent thrombosis (0.3% vs. 1.6%, p < 0.001), compared with those in the ZES group. Furthermore, there was a numerically lower rate of target lesion revascularization (1.2% vs. 2.2%, p = 0.051) in the EES group than in the ZES group. Conclusions: In this propensity-matched comparison, EES seems to be superior to ZES in reducing TLF and stent thrombosis in patients with AMI.

Original languageEnglish
Pages (from-to)936-945
Number of pages10
JournalJACC: Cardiovascular Interventions
Volume5
Issue number9
DOIs
Publication statusPublished - 2012 Sep

Keywords

  • acute myocardial infarction
  • everolimus-eluting stents
  • percutaneous coronary intervention
  • zotarolimus-eluting stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: A propensity score-matched analysis'. Together they form a unique fingerprint.

  • Cite this

    Chen, K. Y., Rha, S. W., Wang, L., Li, Y. J., Li, G. P., Poddar, K. L., Park, J. Y., Choi, C. U., Park, C. G., Seo, H. S., Oh, D. J., Jeong, M. H., Ahn, Y. K., Hong, T. J., Kim, Y. J., Hur, S. H., Seong, I. W., Chae, J. K., Cho, M. C., ... Park, S. J. (2012). Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: A propensity score-matched analysis. JACC: Cardiovascular Interventions, 5(9), 936-945. https://doi.org/10.1016/j.jcin.2012.05.009